ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Pretreatment with Azacitidine Achieves 28-Month Remission

August 30, 2013

NCI Sends A Second Letter To Groups About Carboplatin

October 22, 2010

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

NIH Orders Duke Medical Center To Stop Enrollment In Human Research Studies

May 14, 1999

Referral Pattern Change Needed For Quality Care, AACR/ASCO Told

May 16, 1975

FDA Approves Avastin For Recurrent NSCLC

October 27, 2006